Trials / Terminated
TerminatedNCT02596555
Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- Prof. Stavros Konstantinides, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, multicenter, multinational, phase IV, interventional single-armed (management) trial will focus on the safety, efficacy and cost-effectiveness of a new oral anticoagulant in the treatment of patients with acute intermediate-risk PE based on validated imaging (echocardiographic or CT angiographic) and laboratory biomarker (circulating levels of cardiac troponins and natriuretic peptides) parameters and their combinations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dabigatran | Low molecular weight heparin for 72 hours followed by 6 months of dabigatran |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2020-02-01
- Completion
- 2020-02-01
- First posted
- 2015-11-04
- Last updated
- 2020-02-17
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02596555. Inclusion in this directory is not an endorsement.